Allergic rhinitis-induced nasal congestion: Its impact on sleep quality

Primary Care Respiratory Journal

Volumn 17, Issue 1, 2008, Pages 7-18

  Storms, William ^a  

^a William Storms Allergy Clinic   (United States)

Author keywords

Allergic rhinitis (AR); Congestion; Intranasal corticosteroids (INS); Quality of life (QOL); Sleep; Treatment

Indexed keywords

ANTIHISTAMINIC AGENT; AZELASTINE; BECLOMETASONE DIPROPIONATE; BUDESONIDE; CETIRIZINE; CORTICOSTEROID; DECONGESTIVE AGENT; FEXOFENADINE; FLUNISOLIDE; FLUTICASONE; FLUTICASONE PROPIONATE; MOMETASONE FUROATE; MONTELUKAST; PSEUDOEPHEDRINE; TRIAMCINOLONE ACETONIDE; XYLOMETAZOLINE;

ALLERGIC RHINITIS; CLINICAL TRIAL; DAYTIME SOMNOLENCE; DISEASE ASSOCIATION; DRUG BIOAVAILABILITY; DRUG SAFETY; HUMAN; INFLAMMATORY CELL; MORBIDITY; NASAL PRURITUS; NOSE CONGESTION; NOSE POLYP; OCULAR PRURITUS; PERFORMANCE; QUALITY OF LIFE; REACTION TIME; REVIEW; RHINORRHEA; RHINOSINUSITIS; SIDE EFFECT; SLEEP; SLEEP DISORDERED BREATHING; SNEEZING; SYMPTOMATOLOGY; TACHYCARDIA; URINE RETENTION; XEROSTOMIA;

ANTI-ALLERGIC AGENTS; GLUCOCORTICOIDS; HUMANS; NASAL OBSTRUCTION; QUALITY OF LIFE; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; SLEEP; SLEEP DISORDERS;

EID: 40949099065     PISSN: 14714418     EISSN: 14751534     Source Type: Journal    
DOI: 10.3132/pcrj.2008.00001     Document Type: Review

References (119)

1. Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol 2001;108:2-8.
2. Bousquet J, van Cauwenberge P, Khaltaev N; Aria Workshop Group; World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108:147-336.
3. International Consensus Report on the diagnosis and management of rhinitis. International Rhinitis Management Working Group. Allergy 1994;49:1-34.
4. Sibbald B. Epidemiology of allergic rhinitis. In: Burr ML, ed. Epidemiology of clinical allergy. Monographs in Allergy Basel:Karger;1993. p.61-79.
5. Wuthrich B, Schindler C, Leuenberger P, Ackermann-Liebrich U. Prevalence of atopy and pollinosis in the adult population of Switzerland (SAPALDIA study). Int Arch Allergy Immunol 1995;106:149-56.
6. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 2004;24:758-64.
7. Allergies in America: A landmark survey of nasal allergy sufferers: Executive Summary. Available for URL: http://www.myallergiesinamerica.com/
8. Blaiss M, Reigel T, Philpot E. A study to determine the impact of rhinitis on sufferers' sleep and daily routine [abstract]. J Allergy Clin Immunol 1999;115:197:787.
9. Leger D, Annesi-Maesano I, Carat F et al. Allergic rhinitis and its consequences on quality of sleep. Arch Intern Med 2006;166:1744-8.
10. McNicholas WT, Tarlo S, Cole P et al. Obstructive apneas during sleep in patients with seasonal allergic rhinitis. Am Rev Respir Dis 1982;126:625-8.
11. Young T, Finn L, Kim H. Nasal obstruction as a risk factor for sleep-disordered breathing. The University of Wisconsin Sleep and Respiratory Research Group. J Allergy Clin Immunol 1997;99:S757-62.
12. Lavie P, Gertner R, Zomer J, Podoshin L. Breathing disorders in sleep associated with "microarousals" in patients with allergic rhinitis. Acta Otolaryngol 1981;92:529-33.
13. Flemons WW, Tsai W. Quality of life consequences of sleep-disordered breathing. J Allergy Clin Immunol 1997;99:S750-6.
14. Blaiss MS. Quality of life in allergic rhinitis. Ann Allergy Asthma Immunol 1999;83:449-54.
15. Wilken JA, Berkowitz R, Kane R. Decrements in vigilance and cognitive functioning associated with ragweed-induced allergic rhinitis. Ann Allergy Asthma Immunol 2002;89:372-80.
16. Marshall PS, O'Hara C, Steinberg P. Effects of seasonal allergic rhinitis on selected cognitive abilities. Ann Allergy Asthma Immunol 2000;84:403-10.
17. Kessler RC, Almeida DM, Berglund P, Stang P. Pollen and mold exposure impairs the work performance of employees with allergic rhinitis. Ann Allergy Asthma Immunol 2001;87:289-95.
18. Price D, Bond C, Bouchard J et al. International Primary Care Respiratory Group (IPCRG) guidelines: management of allergic rhinitis. Prim Care Resp J 2006;15:58-70. doi:10.1016/j.pcrj.2005.11.002
19. Juniper EF, Guyatt GH, Dolovich J. Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: development and testing of a questionnaire for clinical trials. J Allergy Clin Immunol 1994;93:413-23.
20. Shedden A. Impact of nasal congestion on quality of life and work productivity in allergic rhinitis. Findings from a large online survey. Treat Respir Med 2005;4:439-46.
21. Juniper EF, Rohrbaugh T, Meltzer EO. A questionnaire to measure quality of life in adults with nocturnal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2003;111:484-90.
22. Juniper EF, Thompson AK, Ferrie PJ, Roberts JN. Development and validation of the Mini Rhinoconjunctivitis Quality of Life Questionnaire. Clin Exp Allergy 2000;30:132-40.
23. Craig TJ, Teets S, Lehman EB, Chinchilli VM, Zwillich C. Nasal congestion secondary to allergic rhinitis as a cause of sleep disturbance and daytime fatigue and the response to topical nasal corticosteroids. J Allergy Clin Immunol 1998;101:633-7.
24. Hughes K, Glass C, Ripchinski M et al. Efficacy of the topical nasal steroid budesonide on improving sleep and daytime somnolence in patients with perennial allergic rhinitis. Allergy 2003;58:380-5.
25. Storms WW. Pharmacologic approaches to daytime and nighttime symptoms of allergic rhinitis. J Allergy Clin Immunol 2004;114:S146-53.
26. Rappai M, Collop N, Kemp S, deShazo R. The nose and sleep-disordered breathing. Chest 2003;124:2309-23.
27. Zwillich CW, Pickett C, Hanson FN, Weil JV. Disturbed sleep and prolonged apnea during nasal obstruction in normal men. Am Rev Respir Dis 1981;124:158-60.
28. Olsen KD, Kern EB, Westbrook PR. Sleep and breathing disturbance secondary to nasal obstruction. Otolaryngol Head Neck Surg 1981;89:804-10.
29. Staevska MT, Mandajieva MA, Dimitrov VD. Rhinitis and sleep apnea. Curr Allergy Asthma Reports 2004;4:193-9.
30. Guilleminault C, Stoohs R, Clerk A, Simmons J, Labanowski M. From obstructive sleep apnea syndrome to upper airway resistance syndrome: consistency of daytime sleepiness. Sleep 1992;15:513-16.
31. Sher AE. An overview of sleep disordered breathing for the otolaryngologist. Ear Nose Throat J 1999;78:a694-5.
32. Hansen I, Klimek L, Mösges R, Hormann K. Mediators of inflammation in the early and the late phase of allergic rhinitis. Curr Opin Allergy Clin Immunol 2004;4:159-63.
33. Gelfand EW. Inflammatory mediators in allergic rhinitis. J Allergy Clin Immunol 2004;114:S135-8.
34. Baraniuk JN. Pathogenesis of allergic rhinitis. J Allergy Clin Immunol 1997;99:S763-72.
35. Rundcrantz H. Postural variations of nasal patency. Acta Otolaryngol 1969;68:435-43.
36. Smolensky MH, Reinberg A, Labrecque G. Twenty-four hour pattern in symptom intensity of viral and allergic rhinitis: treatment implications. J Allergy Clin Immunol 1995;95:1084-96.
37. Reinberg A, Gervais P, Levi F et al. Circadian and circannual rhythms of allergic rhinitis: an epidemiologic study involving chronobiologic methods. J Allergy Clin Immunol 1988;81:51-62.
38. Aoyagi M, Watanabe H, Sekine K et al. Circadian variation in nasal reactivity in children with allergic rhinitis: Correlation with the activity of eosinophils and basophilic cells. Int Arch Allergy Immunol 1999;120:95-9.
39. Ferguson BJ. Influences of allergic rhinitis on sleep. Otolaryngol Head Neck Surg 2004;130:617-29.
40. Krouse HJ, Davis JE, Krouse JH. Immune mediators in allergic rhinitis and sleep. Otolaryngol Head Neck Surg 2002;126:607-13.
41. Mullington JM, Hinze-Selch D, Pollmacher T. Mediators of inflammation and their interaction with sleep: relevance for chronic fatigue syndrome and related conditions. Ann NY Acad Sci 2001;933:201-10.
42. Tashiro M, Mochizuki H, Iwabuchi K et al. Roles of histamine in regulation of arousal and cognition: functional neuroimaging of histamine H1 receptors in human brain. Life Sci 2002;72:409-14.
43. Onodera K, Miyazaki S, Imaizumi M et al. Improvement by FUB 181, a novel histamine H3-receptor antagonist, of learning and memory in the elevated plus-maze test in mice. Naunyn-Schmiedeberg Arch Pharmacol 1998;357:508-13.
44. Parmentier R, Ohtsu H, Djebbara-Hannas et al. Anatomical, physiological, and pharmacological characteristics of histidine decarboxylase knock-out mice: evidence for the role of brain histamine in behavioral and sleep-wake control. J Neurosci 2002;22:7695-711.
45. McColley SA, Carroll JL, Curtis S, Loughlin GM, Sampson HA. High prevalence of allergic sensitization in children with habitual snoring and obstructive sleep apnea. Chest 1997;111:170-3.
46. van Cauwenberge P, Bachert C, Passalacqua G et al. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy 2000;55:116-34.
47. Murray JJ, Nathan RA, Bronsky EA, Olufade AO, Chapman D, Kramer B. Comprehensive evaluation of cetirizine in the management of seasonal allergic rhinitis: impact on symptoms, quality of life, productivity, and activity impairment. Allergy Asthma Proc 2002;23:391-8.
48. Meltzer EO, Casale TB, Nathan RA et al. Once-daily fexofenadine HCl improves quality of life and reduces work and activity impairment in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1999;83:311-17.
49. Camelo-Nunes IC. New antihistamines: a critical review. J Pediatr (Rio J) 2006;82:173-80.
50. Kakumanu S, Glass C, Craig T. Poor sleep and daytime somnolence in allergic rhinitis: significance of nasal congestion. Am J Respir Med 2002;1:195-200.
51. Vuurman EFPM, van Veggel LMA, Uiterwijk MMC et al. Seasonal allergic rhinitis and antihistamine effects on children's learning. Ann Allergy 1993;71:121-6.
52. Weiler JM, Bloomfield JR, Woodworth GG et al. Effects of fexofenadine, diphenhydramine, and alcohol on driving performance: a randomized, placebo-controlled trial in the Iowa driving simulator. Ann Intern Med 2000;132:354-63.
53. Tashiro M, Sakurada Y, Iwabuchi K et al. Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography. J Clin Pharmacol 2004;44:890-900.
54. Cetirizine hydrochloride [package insert]. New York, NY: Pfizer Inc; 2007.
55. Saengpanich S, Assanasen P, de Tineo M et al. Effects of intranasal azelastine on the response to nasal allergen challenge. Laryngoscope 2002;112:47-52.
56. Golden S, Teets SJ, Lehman EB et al. Effect of topical nasal azelastine on the symptoms of rhinitis, sleep, and daytime somnolence in perennial allergic rhinitis. Ann Allergy Asthma Immunol 2000;85:53-7.
57. Ramey JT, Bailen E, Lockey RF. Rhinitis medicamentosa. J Investig Allergol Clin Immunol 2006;16:148-55.
58. Dykewicz MS, Fineman S, Skoner DP et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 1998;81:478-518.
59. Caenen M, Hamels K, Deron P, Clement P. Comparison of decongestive capacity of xylometazoline and pseudoephedrine with rhinomanometry and MRI. Rhinology 2005;43:205-09.
60. Moinuddin R, deTineo M, Maleckar B et al. Comparison of the combinations of fexofenadine-pseudoephedrine and loratadine-montelukast in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2004;92:73-9.
61. Fokkens WJ, Godthelp T, Holm AF et al. Allergic rhinitis and inflammation: the effect of nasal corticosteroid therapy. Allergy 1997;52:29-32.
62. Juliusson S, Holmberg K, Karlsson G et al. Mast cells and mediators in the nasal mucosa after allergen challenge. Effects of four weeks' treatment with topical glucocorticoid. Clin Exp Allergy 1993;23:591-9.
63. Rak S, Jacobson MR, Sudderick RM et al. Influence of prolonged treatment with topical corticosteroid (fluticasone propionate) on early and late phase nasal responses and cellular infiltration in the nasal mucosa after allergen challenge. Clin Exp Allergy 1994;24:930-9.
64. Davies RJ, Nelson HS. Once-daily mometasone furoate nasal spray: efficacy and safety of a new intranasal glucocorticoid for allergic rhinitis. Clin Ther 1997;19:27-38.
65. Meltzer EO, Orgel HA, Bronsky EA et al. A dose-ranging study of fluticasone propionate aqueous nasal spray for seasonal allergic rhinitis assessed by symptoms, rhinomanometry, and nasal cytology. J Allergy Clin Immunol 1990;86:221-30.
66. DeWester J, Philpot EE, Westlund RE et al. The efficacy of intranasal fluticasone propionate in the relief of ocular symptoms associated with seasonal allergic rhinitis. Allergy Asthma Proc 2003;24:331- 7.
67. Schenkel E, LaForce C, Gates D. Mometasone furoate nasal spray in seasonal allergic rhinitis. Allergy Clin Immunol Int 2007;19:50-3
68. Kaiser HB. Naclerio RM, Given J et al. Fluticasone furoate nasal spray: a single treatment option for the symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol 2007;119:1430-7.
69. Jen A, Baroody F, de Tineo M et al. As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol 2000;105:732-8.
70. Wilson AM, Sims EJ, McFarlane LC et al. Effects of intranasal corticosteroids on adrenal, bone, and blood markers of systemic activity in allergic rhinitis. J Allergy Clin Immunol 1998;102:598-604.
71. Craig TJ, Hanks CD, Fisher LH. How do topical nasal corticosteroids improve sleep and daytime somnolence in allergic rhinitis? J Allergy Clin Immunol 2005;116:1264-6.
72. Craig TJ, Mende C, Hughes K, Kakumanu S, Lehman EB, Chinchilli V. The effect of topical nasal fluticasone on objective sleep testing and the symptoms of rhinitis, sleep, and daytime somnolence in perennial allergic rhinitis. Allergy Asthma Proc 2003;24:53-8.
73. Gawchik S, Goldstein S, Prenner B, John A. Relief of cough and nasal symptoms associated with allergic rhinitis by mometasone furoate nasal spray. Ann Allergy Asthma Immunol 2003;90:416-21.
74. Mintz M, Garcia J, Diener P, Liao Y, Dupclay L, Georges G. Triamcinolone acetonide aqueous nasal spray improves nocturnal rhinitis-related quality of life in patients treated in a primary care setting: the Quality of Sleep in Allergic Rhinitis study. Ann Allergy Asthma Immunol 2004;92:255- 61.
75. Ratner PH, Howland WC III, Arastu R et al. Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast. Ann Allergy Asthma Immunol 2003;90:536-42.
76. Kiely JL, Nolan P, McNicholas WT. Intranasal corticosteroid therapy for obstructive sleep apnoea in patients with co-existing rhinitis. Thorax 2004;59:50-5.
77. Berger WE, Nayak AS, Staudinger HW. Mometasone furoate improves congestion in patients with moderate-to-severe seasonal allergic rhinitis. Ann Pharmacother 2005;39:1984-9.
78. Mansfield LE, Diaz G, Posey CR, Flores-Neder J. Sleep disordered breathing and daytime quality of life in children with allergic rhinitis during treatment with intranasal budesonide. Ann Allergy Asthma Immunol 2004;92:240-4.
79. Gurevich F, Glass C, Davies M et al. The effect of intranasal steroid budesonide on the congestion-related sleep disturbance and daytime somnolence in patients with perennial allergic rhinitis. Allergy Asthma Proc 2005;26:268-74.
80. Bisgaard H, Olsson P, Bende M. Effect of leukotriene D4 on nasal mucosal blood flow, nasal airway resistance and nasal secretions in humans. Clin Allergy 1986;16:289-97.
81. Okuda M, Watase T, Mezawa A, Liu CM. The role of leukotriene D4 in allergic rhinitis. Ann Allergy 1988;60:537-40.
82. White M. Mediators of inflammation and the inflammatory process. J Allergy Clin Immunol 1999;103:S378-81.
83. Naclerio R. Clinical manifestations of the release of histamine and other inflammatory mediators. J Allergy Clin Immunol 1999;103:S382-5.
84. Philip G, Malmstrom K, Hampel FC et al. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy 2002;32:1020-8.
85. van Adelsberg J, Philip G, LaForce CF et al. Randomized controlled trial evaluating the clinical benefit of montelukast for treating spring seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2003;90:214-22.
86. Nayak AS, Philip G, Lu S et al. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann Allergy Asthma Immunol 2002a;88:592- 600.
87. Can D, Tanac R, Demir E, Gulen F, Veral A. Efficacy of pollen immunotherapy in seasonal allergic rhinitis. Pediatrics International 2007;49:64-69.
88. Kirtsreesakul V, Naclerio RM. Role of allergy in rhinosinusitis. Curr Opin Allergy Clin Immunol 2004;4:17-23.
89. Slavin RG. Sinusitis in adults and its relation to allergic rhinitis, asthma, and nasal polyps. J Allergy Clin Immunol 1988;82:950-6.
90. Berrettini S, Carabelli A, Sellari-Franceschini S et al. Perennial allergic rhinitis and chronic sinusitis: correlation with rhinologic risk factors. Allergy 1999;54:242-8.
91. Hellings PW, Fokkens WJ. Allergic rhinitis and its impact on otorhinolaryngology. Allergy 2006;61:656-64.
92. Mygind N, Dahl R, Bachert C. Nasal polyposis, eosinophil dominated inflammation, and allergy. Thorax 2000;55:79-83.
93. Fokkens W, Lund V, Bachert C et al. EAACI position paper on rhinosinusitis and nasal polyps executive summary. Allergy 2005;60:583-601.
94. Bachert C, Hörmann K, Mösges R et al. An update on the diagnosis and treatment of sinusitis and nasal polyposis. Allergy 2003;58:176-91.
95. Serrano E, Neukirch F, Pribil C et al. Nasal polyposis in France: impact on sleep and quality of life. J Laryngol Otol 2005;119:543- 9.
96. Small CB, Hernandez J, Reyes A et al. Efficacy and safety of mometasone furoate nasal spray in nasal polyposis. J Allergy Clin Immunol 2005;116:1275-81.
97. Vendelbo Johansen L, Illum P, Kristensen S, Winther L, Vang Petersen S, Synnerstad B. The effect of budesonide (Rhinocort® ) in the treatment of small and medium-sized nasal polyps. Clin Otolaryngol 1993;18:524-7.
98. Lildholdt T, Rundcrantz H, Lindqvist N. Efficacy of topical corticosteroid powder for nasal polyps: a double-blind, placebo-controlled study of budesonide. Clin Otolaryngol Allied Sci 1995;20:26-30.
99. Tos M, Svendstrup F, Arndal H et al. Efficacy of an aqueous and a powder formulation of nasal budesonide compared in patients with nasal polyps. Am J Rhinol 1998;12:183-9.
100. Holmberg K, Juliusson S, Balder B, Smith DL, Richards DH, Karlsson G. Fluticasone propionate aqueous nasal spray in the treatment of nasal polyposis. Ann Allergy Asthma Immunol 1997;78:270-6.
101. Lund VJ, Flood J, Sykes AP, Richards DH. Effect of fluticasone in severe polyposis. Arch Otolaryngol Head Neck Surg 1998;124:513-18.
102. Penttilä M, Poulsen P, Hollingworth K, Holmström M. Dose-related efficacy and tolerability of fluticasone propionate nasal drops 400?g once daily and twice daily in the treatment of bilateral nasal polyposis: a placebo-controlled randomized study in adult patients. Clin Exp Allergy 2000;30:94-102.
103. Blaiss MS. Expanding the evidence base for the medical treatment of nasal polyposis. J Allergy Clin Immunol 2005;116:1272-4.
104. Nasonex [package insert]. Kenilworth, NJ: Schering Corporation; 2005.
105. Stjarne P, Mosges R, Jorissen M et al. A randomized controlled trial of mometasone furoate nasal spray for the treatment of nasal polyposis. Arch Otolaryngol Head Neck Surg 2006;132:179-85.
106. Jankowski R, Schrewelius C, Bonfils P et al. Efficacy and tolerability of budesonide aqueous nasal spray treatment in patients with nasal polyps. Arch Otolaryngol Head Neck Surg 2001;127:447-52.
107. Filaci F, Passali D, Puxeddu R, Schrewelius C. A randomized controlled trial showing efficacy of once daily intranasal budesonide in nasal polyposis. Rhinology 2000;38:185-90.
108. Meltzer EO, Bachert C, Staudinger H. Treating acute rhinosinusitis: comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo. J Allergy Clin Immunol 2005;116:1289-95.
109. Kenny TJ, Duncavage J, Bracikowski J et al. Prospective analysis of sinus symptoms and correlation with paranasal computed tomography scan. Otolaryngol Head Neck Surg 2001;125:40-3.
110. Small CB, Bachert C, Lund VJ, Moscatello A, Nayak AS, Berger WE. Judicious antibiotic use and intransal corticosteroids in acute rhinosinusitis. Am J Med 2007;120:289-94.
111. Sande MA, Gwaltney JM. Acute community-acquired bacterial sinusitis: continuing challenges and current management. Clin Infect Dis 2004;39:151-8.
112. Gillespie MB, Osguthorpe JD. Pharmacologic management of chronic rhinosinusitis, alone or with nasal polyposis. Curr Allergy Asthma Rep 2004;4:478-85.
113. Barlan IB, Erkan E, Bakir M, Berrak S, Basaran MM. Intranasal budesonide spray as an adjunct to oral antibiotic therapy for acute sinusitis in children. Ann Allergy Asthma Immunol 1997;78:598-601.
114. Yilmaz G, Varan B, Yilmaz T, Gurakan B. Intranasal budesonide spray as an adjunct to oral antibiotic therapy for acute sinusitis in children. Eur Arch Otorhinolaryngol 2000;257:256-9.
115. Meltzer EO, Orgel HA, Backhaus JW et al. Intranasal flunisolide spray as an adjunct to oral antibiotic therapy for sinusitis. J Allergy Clin Immunol 1993; 92:812-23.
116. Meltzer EO, Charous BL, Busse WW, Zinreich SJ, Lorber RR, Danzig MR. Added relief in the treatment of acute recurrent sinusitis with adjunctive mometasone furoate nasal spray. The Nasonex Sinusitis Group. J Allergy Clin Immunol 2000;106:630-7.
117. Nayak AS, Settipane GA, Pedinoff A et al; Nasonex Sinusitis Group. Effective dose range of mometasone furoate nasal spray in the treatment of acute rhinosinusitis. Ann Allergy Asthma Immunol 2002b;89:271-8.
118. University of Michigan Health System Guidelines for Clinical Care: Acute Rhinosinusitis in Adults. Available for URL: http://cme.med.umich.edu/pdf/ guideline/rhino05.pdf
119. Santanello NC, DeMuro-Mercon C, Shah SR et al. Validation of the nighttime symptoms score as a clinically relevant measure of allergic rhinitis. Allergy Asthma Proc 2006;27:231-9.